OBJECTIVE: to analyze the immunohistochemical expression of P27 and CD34 markers as prognostic factors in patients with localized prostate cancer. METHODS: analysis of 100 patients with localized prostate cancer submitted to curative surgery. We carried out the usual histological preparation, followed by immunohistochemistry to detect the accumulation of P27 and CD34 protein followed by statistical analysis. RESULTS: in the evaluation of P27 marker and on the correlation with the variables we found significant difference in Gleason score with positive expression (positive P27) related to lower mean PSA (p = 0.091), lower Gleason score (p < 0.0001) and smaller tumor area in CD34 (p = 0.036). Regarding the CD34 marker at the tumor area, it was observed that the smaller the positive CD34, the lower the PSA value (p < 0.0001) and lower the Gleason score (r = 0.5726, p < 0.0001), and the higher the positive CD34, the higher the staging (r = 0.3305, p <0.0001) and the chance of recurrence (p = 0.002). Patients with higher stage also displayed larger positive CD34 areas (p < 0.0001). CONCLUSION: the markers CD34 and P27 are associated with events specific to prostate cancer, however, only CD34 was able to determine the possibility of biochemical recurrence.
OBJECTIVE: to analyze the immunohistochemical expression of P27 and CD34 markers as prognostic factors in patients with localized prostate cancer. METHODS: analysis of 100 patients with localized prostate cancer submitted to curative surgery. We carried out the usual histological preparation, followed by immunohistochemistry to detect the accumulation of P27 and CD34 protein followed by statistical analysis. RESULTS: in the evaluation of P27 marker and on the correlation with the variables we found significant difference in Gleason score with positive expression (positive P27) related to lower mean PSA (p = 0.091), lower Gleason score (p < 0.0001) and smaller tumor area in CD34 (p = 0.036). Regarding the CD34 marker at the tumor area, it was observed that the smaller the positive CD34, the lower the PSA value (p < 0.0001) and lower the Gleason score (r = 0.5726, p < 0.0001), and the higher the positive CD34, the higher the staging (r = 0.3305, p <0.0001) and the chance of recurrence (p = 0.002). Patients with higher stage also displayed larger positive CD34 areas (p < 0.0001). CONCLUSION: the markers CD34 and P27 are associated with events specific to prostate cancer, however, only CD34 was able to determine the possibility of biochemical recurrence.
Authors: Márk Híveš; Jana Jurečeková; Ján Kliment; Marián Grendár; Peter Kaplán; Róbert Dušenka; Daniel Evin; Marta Vilčková; Klaudia Híveš Holečková; Monika Kmeťová Sivoňová Journal: Cancer Genomics Proteomics Date: 2022 May-Jun Impact factor: 4.069
Authors: Hüseyin Sirma; Margarethe Broemel; Laura Stumm; Tina Tsourlakis; Stefan Steurer; Pierre Tennstedt; Georg Salomon; Uwe Michl; Alexander Haese; Ronald Simon; Guido Sauter; Thorsten Schlomm; Sarah Minner Journal: Oncol Lett Date: 2013-09-04 Impact factor: 2.967
Authors: Martina Kluth; Ramin Ahrary; Claudia Hube-Magg; Malik Ahmed; Heinke Volta; Catina Schwemin; Stefan Steurer; Corinna Wittmer; Waldemar Wilczak; Eike Burandt; Till Krech; Meike Adam; Uwe Michl; Hans Heinzer; Georg Salomon; Markus Graefen; Christina Koop; Sarah Minner; Ronald Simon; Guido Sauter; Thorsten Schlomm Journal: Oncotarget Date: 2015-09-29
Authors: Paweł Stawerski; Małgorzata Wagrowska-Danilewicz; Olga Stasikowska-Kanicka; Elżbieta Tuka; Marian Danilewicz Journal: Contemp Oncol (Pozn) Date: 2013-10-07